tga semaglutide Australia's TGA has approved semaglutide - TGAOzempic semaglutide TGA Semaglutide: Understanding the Regulatory Landscape and Safety Alerts

GLP-1 Australia Chemist Warehouse The Therapeutic Goods Administration (TGA) in Australia plays a crucial role in ensuring the safety and efficacy of medicines available to the public. Recently, semaglutide, a medication widely recognized for its use in managing type 2 diabetes mellitus and/or obesity, has been at the forefront of TGA's attention.Semaglutide - medicine shortage information This article delves into the TGA semaglutide landscape, exploring its approvals, safety warnings, and the regulatory actions being taken to protect consumers.

TGA Approvals and Indications for Semaglutide

Semaglutide, a GLP-1 RA (glucagon-like peptide-1 receptor agonist), has seen significant regulatory milestones in Australia. It is prescribed under brand names such as Ozempic and Wegovy. Ozempic is primarily indicated as an anti-diabetic medication used for the treatment of type 2 diabetes and for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular diseaseTGA issues fresh warning for Ozempic and other high .... In a significant development, semaglutide Wegovy (Novo Nordisk) was approved by the TGA for weight management2025年12月1日—The TGA has identified all GLP-1 RA class products currently marketed in Australia are affected by the warning, including:semaglutide(Ozempic, .... Furthermore, Australia's TGA has approved semaglutide for reducing kidney disease progression in patients with type 2 diabetes and chronic kidney disease, highlighting its expanding therapeutic applications. Wegovy 2.4mg now approved to reduce heart risks in adults with high BMI and CVD signifies a further expansion of its benefits.

Safety Alerts and Warnings Issued by the TGA

The increasing popularity and off-label promotion of semaglutide for weight loss have prompted the TGA to issue several safety alerts. One of the most prominent concerns has been the proliferation of fake semaglutide, also known as Ozempic, being illegally imported into Australia. The TGA issues weight-loss drug safety alerts and has specifically warned consumers about Ozempic scams2023年1月8日—Ozempic is an injectable medicine designed for diabetes, but it's being promoted online for its side effect of weight loss..

A critical aspect of these warnings pertains to compounded versions of semaglutideCompounding safety information: semaglutide-like products. The TGA has stated that compounded semaglutide-like products have not been evaluated for safety, quality and efficacy by the regulatory body and are therefore considered 'unapproved' therapeutic goodsOzempic. Brand name: Ozempic. Form & strength:semaglutide 1.34 mg/mL injection, 1 x 3 mL pen device. Manufacturer: Novo Nordisk Pharmaceuticals Pty.. This has led to the TGA's decision to stop the compounding of medicines containing semaglutideCompounded semaglutide-like products: TGA Australia warns .... Diabetes Australia and Diabetes Victoria have voiced their support for this decision, emphasizing the potential risks associated with unverified products.

The TGA has also issued warnings regarding the potential for increased reporting of suicidal thoughts or ideation associated with GLP-1 RA class products, including semaglutide. As a result, in September 2023, the TGA issued advice that semaglutide prescriptions should not be issued without a compelling clinical reason, particularly for new patientsAmy Schumer Explains Why She Stopped Taking Ozempic - IMDb. This advisory reflects a proactive approach to managing potential risks associated with the medication. The TGA has also updated its stance on advertising, with TGA updates on advertising rules for weight-loss medicines being implemented to curb misleading promotionsSemaglutide receives TGA approval for CKD in diabetes.

Regulatory Actions Against Illegal Promotion and Compounding

The TGA has taken a firm stance against the illegal promotion and distribution of semaglutide. Reports indicate that the TGA threatens heavy fines for promoting semaglutide and is willing to prosecute individuals and companies involved in unauthorized advertising. The TGA is threatening jail time and imposing substantial fines, up to $1 million, on social media influencers and advertisers who promote the drug for weight loss purposes without proper authorization.

Furthermore, the TGA has been actively engaging in consultations to strengthen regulations around compounding. A targeted consultation was opened to update the Therapeutic Goods Regulations 1990 to prevent pharmacists from compounding semaglutide.2020年10月30日—This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. This move aims to ensure that only TGA-approved semaglutide products, manufactured by authorized pharmaceutical companies like Novo Nordisk Pharmaceuticals Pty, are available to the public.2025年10月29日—Side effects were similar to those seen with the injectable GLP-1 RAs likesemaglutide, including nausea, vomiting and gastrointestinal issues. Novo Nordisk is the sole pharmaceutical company with TGA-approved products containing semaglutide.

Understanding Semaglutide Varieties and Shortages

The supply of semaglutide has also been impacted by shortages. Information regarding semaglutide - medicine shortage information is regularly updated by regulatory bodies.2025年12月1日—The TGA has identified all GLP-1 RA class products currently marketed in Australia are affected by the warning, including:semaglutide(Ozempic, ... For instance, the 1.TGA updates on advertising rules for weight-loss medicines... Semaglutide and tirzepatide potential to transform type 1 diabetes treatment.34 mg/mL injection, 1 x 3 mL pen device formulation of Ozempic by Novo Nordisk has seen specific availability issues where certain presentations might remain available for dispensing but not for prescribing, necessitating careful management by healthcare professionals.

Moving Forward with Semaglutide and GLP-1 RAs in Australia

The TGA semaglutide narrative underscores the importance of regulatory oversight in the face of rapidly evolving pharmaceutical landscapes. While semaglutide offers significant therapeutic benefits for type 2 diabetes mellitus and/or obesity, and even for cardiovascular risk reduction, its use must be guided by official approvals and safety recommendations2025年12月1日—Australia's drugs regulator has issued a fresh warning for users of high-profile injectable diabetes and weight-loss drugs such as Ozempic.. Consumers are urged to exercise extreme caution regarding semaglutide and semaglutide-like products, and to seek guidance from qualified healthcare professionals.2025年12月1日—The TGA has identified all GLP-1 RA class products currently marketed in Australia are affected by the warning, including:semaglutide(Ozempic, ...

The discussions around switching from semaglutide to tirzepatide also highlight the ongoing research and development in this therapeutic class. The potential for future innovations, such as oral GLP-1 medications, which are undergoing submissions for TGA approval, suggests a dynamic future for diabetes and obesity management in Australia.TGA updates on advertising rules for weight-loss medicines However, the consistent message from the TGA remains: prioritize safety, efficacy, and adherence to approved therapeutic guidelines when considering semaglutide and its related treatmentsDiabetes Victoria supports the Therapeutic Goods Administration's decision to stop the compounding ofsemaglutide-like products. Use extreme caution. While .... The semaglutide supplies currently available in Australia are primarily intended for patients with type 2 diabetes.TGA issues two new safety alerts for GLP-1 RA products